Emergent BioSolutions (NYSE:EBS) Rating Lowered to “Hold” at StockNews.com

StockNews.com lowered shares of Emergent BioSolutions (NYSE:EBS) from a buy rating to a hold rating in a report issued on Wednesday morning.

EBS has been the subject of several other reports. Rodman & Renshaw reiterated a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark raised their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Price Performance

EBS opened at $9.48 on Wednesday. The business has a fifty day moving average of $8.75 and a 200 day moving average of $8.18. The stock has a market cap of $513.36 million, a P/E ratio of -2.31 and a beta of 1.57. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions has a 52-week low of $1.42 and a 52-week high of $15.10.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its holdings in Emergent BioSolutions by 155.3% in the first quarter. BNP Paribas Financial Markets now owns 163,589 shares of the biopharmaceutical company’s stock worth $414,000 after purchasing an additional 99,520 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Emergent BioSolutions by 14.7% in the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock worth $8,631,000 after buying an additional 436,911 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Emergent BioSolutions by 22.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 4,409 shares in the last quarter. Tidal Investments LLC bought a new position in shares of Emergent BioSolutions during the 1st quarter worth approximately $34,000. Finally, Cetera Advisors LLC purchased a new stake in Emergent BioSolutions during the first quarter valued at approximately $428,000. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.